Du är här


FIT Biotech Oy: FIT Biotech reports change in the composition of the Board of Directors

PRESS RELEASE 12 August 2015, at 20.00

FIT Biotech reports change in the composition of the Board of Directors

FIT Biotech Ltd (NASDAQ: FITBIO), a Finnish biotechnology company, today
announced a change in the composition of the Board of Directors. Ms Tina
Nyfors, who has been serving at the Board since 2014, resigned today due to
personal circumstances.

Mr. Rabbe Slätis, the Chairman of the Board, stated: "We would like to thank
Ms Nyfors for her excellent contribution to the company and to our Board
work. It has been a true pleasure working together. We would have liked to
continue the working relationship with her and thus are sorry to see her go,
but we of course understand her situation and respect her decision. We wish
Ms Nyfors all the best for the future, and I'm sure our paths will cross
again in the future."

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy

Phone: +358 40 843 5695

FIT Biotech Oy in brief:

FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA
vaccines and gene therapy. The company bases its products on its patented GTU
® (Gene Transport Unit) technology. Through GTU technology, FIT Biotech
develops DNA vaccines in order to both prevent and also treat various
diseases. Identified application areas include HIV, tuberculosis (and other
infectious diseases) as well as gene therapy (cancer, autoimmune diseases).
Other application areas are under development. FIT Biotech Oy is listed on
NASDAQ First North (ticker: FITBIO). More information can be found

Certified Advisor: Translink Corporate Finance Oy, Kluuvikatu 5, 00100
Helsinki. Tel: +358-20-743 2790


The information contained herein is not for publication or distribution,
directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, South
Africa or the United States. These written materials do not constitute an
offer of securities for sale in the United States, nor may the securities be
offered or sold in the United States absent registration or an exemption from
registration as provided in the U.S. Securities Act of 1933, as amended, and
the rules and regulations thereunder. No part of the company shares or any
other securities will be registered in the United States nor will the
securities be offered to the public in the United States.

In certain states, the issue, use and/or sale of securities is subject to
special legal or legislative restrictions. The Company or its advisors
assumes no responsibility in the event there is a violation by any person of
such restrictions.

The information contained herein shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of the
securities referred to herein in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration, exemption from
registration or qualification under the securities laws of any such
jurisdiction. Investors must neither accept any offer for, nor acquire, any
securities to which this document refers, unless they do so on the basis of
the information contained in the applicable prospectus published or offering
circular distributed by the Company.

The Company has not given authorisation for offering the securities to the
public in any other member state of the European Economic Area than Finland.
Save for Finland, measures for offering the securities to the public have not
been and will not be taken in any member state of the European Economic Area
having implemented the Prospectus Directive (each a 'Relevant Member State')
in a way that would require the publication of a prospectus in the Relevant
Member State. As a consequence, the securities can only be offered in the
Relevant Member States to (a) legal persons that are qualified investors as
defined in the Prospectus Directive or (b) in any other situation mentioned
in Article 3(2) of the Prospectus Directive. In this paragraph, the
expression 'offer securities to the public' means communication by any means
presenting sufficient information on the terms of the offer and the
securities to be offered, so as to enable an investor to decide to use,
purchase or subscribe to these securities, as the expression may vary due to
the implementation measures taken in the Member State. The expression
'Prospectus Directive' refers to Directive 2003/71/EC (as amended, including
the 2010 Amending Directive, to the extent that it has been implemented in
the Relevant Member State), and it includes all relevant implementation
measures in the Relevant Member State, and the expression '2010 Amending
Directive' refers to Directive 2010/73/EC.

The information presented herein is targeted only at (i) persons outside the
United Kingdom or (ii) persons with professional investment experience in the
manner referred to in Article 19(5) of the United Kingdom Financial Services
and Markets Act (Financial Promotion) Order 2005 and (iii) high net worth
entities specified in Article 49(2) of the Order or other persons to which
the document can be lawfully communicated (all jointly the 'Relevant
Persons'). Any investment activity to which this communication relates will
only be available to and will only be engaged with, Relevant Persons. Any
person who is not a Relevant Person should not act or rely on this document
or any of its contents.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.